Sector News

Sanofi strategy exec Mansuri jumps ship ahead of new CEO’s big reveal

November 25, 2019
Life sciences

New Sanofi CEO Paul Hudson is days away from unveiling his plans for the French drugmaker, but the company’s top strategy executive won’t wait that long to leave.

Muzammil Mansuri, Sanofi’s executive vice president of strategy and business development since February 2016, will retire by the end of the month, a spokeswoman confirmed. Reuters first reported the departure Friday morning.

Mansuri has played a “key role” in Sanofi’s strategic moves over the last four years, overseeing recent acquisitions and “structuring partnerships and alliances that contributed to the deployment of our strategy and growth,” Sanofi’s spokeswoman said. The retirement had been planned, she added.

Sanofi’s recent acquisitions include two wrapped up last year: the hemophilia-focused Bioverativ for $11.6 billion and nanobody biotech Ablynx for $4.8 billion. The moves were designed to reduce the drugmaker’s reliance on diabetes and cardiovascular meds, which have been struggling against pricing pressure and stepped-up competition for several years.

With Mansuri’s departure, Sanofi said Alban de La Sablière, its business development head, and Laurent Van Lerberghe, its strategy head, will take on more responsibilities starting Dec. 1.

The news comes a few months into Hudson’s tenure and ahead of an investor event Dec. 10 in Cambridge, Massachusetts. Since he joined Sanofi from Novartis at the beginning of September, Hudson has been touring Sanofi’s facilities to learn as much about the company as possible.

He’s also been reviewing each of the company’s divisions, and Bloomberg reported this week the drugmaker is considering a sale or spinoff of its consumer healthcare business. The group brings in $5 billion annually.

Mansuri joined Sanofi from Gilead Sciences and had prior experience at Bristol-Myers, CGI Pharmaceuticals and Shell Research Limited.

By Eric Sagonowsky

Source: Fierce Pharma

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

LinkedIn Twitter Xing Facebook EmailDifferent from a gluten intolerance, coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are […]

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

LinkedIn Twitter Xing Facebook EmailBone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures. […]

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

LinkedIn Twitter Xing Facebook EmailBelgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK. The acquisition of the site in Windlesham, […]

Send this to a friend